Ratings Biocon Limited

Equities

BIOCON

INE376G01013

Market Closed - NSE India S.E. Other stock markets 07:43:47 2024-05-03 EDT			5-day change	1st Jan Change
305.2 ^INR	-1.83%		+4.65%	+22.25%

04-30	Natural Biocon (India) CFO Passes Away	MT
04-20	Biocon Limited Receives Approval from the South African Health Products Regulatory Authority for its Vertically Integrated, Complex Drug Product Tacrolimus Capsule 0.5mg, 1mg and 5mg Strengths, in South Africa	CI

Summary

The company has a good ESG score relative to its sector, according to Refinitiv.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
The company's profit outlook over the next few years is a strong asset.
For several months, analysts have been revising their EPS estimates roughly upwards.

Weaknesses

One of the major weak points of the company is its financial situation.
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 39.05 times its estimated earnings per share for the ongoing year.
With an enterprise value anticipated at 3.52 times the sales for the current fiscal year, the company turns out to be overvalued.
The company is highly valued given the cash flows generated by its activity.
The company is not the most generous with respect to shareholders' compensation.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
BIOCON LIMITED	+22.25%	4.45B	A-
VERTEX PHARMACEUTICALS INCORPORATED	-1.43%	103B	B+
REGENERON PHARMACEUTICALS, INC.	+8.96%	101B	B+
ARGENX SE	+4.40%	23.07B	B
BIONTECH SE	-12.15%	22.23B	B+
GENMAB A/S	-4.36%	18.05B	A-
WUXI APPTEC CO., LTD.	-39.98%	17.18B	A-
BEIGENE, LTD.	-10.04%	16.94B	B
NEUROCRINE BIOSCIENCES, INC.	+6.79%	14.07B	C+
SAREPTA THERAPEUTICS, INC.	+38.61%	12.35B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes